Drug Profile
PF 5180999
Alternative Names: modified release PF-05180999; MR PF-05180999; PF-05180999; PF-5180999; PF-999Latest Information Update: 04 Sep 2014
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antimigraines; Antipsychotics; Small molecules
- Mechanism of Action Type 2 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Migraine; Schizophrenia
Most Recent Events
- 07 Aug 2014 Discontinued - Phase-I for Migraine (In volunteers) in USA (PO)
- 01 Dec 2013 Phase-I clinical trials in Migraine (in volunteers) in USA (PO)
- 28 Feb 2013 Discontinued - Phase-I for Schizophrenia in USA (PO)